Skip to content

Nestlé Health Science to acquire IM HealthScience for an undisclosed amount

Nestlé Health Science agreed to buy the business of IM HealthSciencefor an undisclosed amount
Jordan Major

Nestlé Health Science (NHSc) ranks as a one of the globally recognized leaders in the nutritional science sector. On August 18, reports emerged that the company has agreed to buy the business of IM HealthScience for an undisclosed amount. The deal involves the takeover of FDgard, IBgard, REMfresh, and Fiber Choice brands by Nestlé.

NHSc offers an extensive consumer health portfolio of industry-leading medical nutrition, consumer, and VMS brands. This deal will expand their coverage while simultaneously increasing the services that they provide.

While commenting on the acquisition, Greg Behar, CEO of Nestlé Health Science, said:

“The IMH products offer proven and trusted solutions for the dietary management of specific digestive problems as well as a separate solution for regulating sleep. IMH’s dedication to developing products to address overall health and wellness by bringing cutting-edge life science and world-class research fits perfectly with our mission of empowering healthier lives through nutrition.”

IM HealthScience (IMH) is the innovator of FDgard and IBgard for the dietary management of FD (Functional Dyspepsia) and IBS (Irritable Bowel Syndrome), respectively. The privately held firm based in Boca Raton, Florida was founded in 2013 by highly experienced pharmaceutical research and development and management executives. The company mainly targets conditions that have a high rate of unmet medical needs.

Some of the areas that they cover include gastrointestinal health, acute care, oncology, pediatric health, allergy, metabolic health, healthy aging, and inborn errors of metabolism.

The chairman and founder of IM HealthScience, Fred Hassan, commented on the acquisition by Nestlé:

“Science, patents, and meaningful differentiation has enabled our company to grow several times faster than the market. IBgard, FDgard, and Fiber Choice have become the number one recommended by gastroenterologists in their segments; and REMfresh ranks as the number one sleep aid recommended by sleep specialists.”

Fiber Choice joined IMH in 2017 through an acquisition. Fiber Choice specializes in prebiotic fibers. On the other hand, REMfresh is a renowned continuous release-and-absorption melatonin (CRA-melatonin) supplement manufactured for sleep.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account?

Services

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.